NCT07073547
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07073547
Title A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Acronym DURGA-2
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Research Site WITHDRAWN Phoenix Arizona 85054 United States Details
Research Site RECRUITING Duarte California 91010 United States Details
Research Site RECRUITING Denver Colorado 80218 United States Details
Research Site RECRUITING Tampa Florida 33612 United States Details
Research Site RECRUITING Atlanta Georgia 30322 United States Details
Research Site RECRUITING Iowa City Iowa 52242 United States Details
Research Site WITHDRAWN Rochester Minnesota 55905 United States Details
Research Site RECRUITING St Louis Missouri 63110 United States Details
Research Site RECRUITING New York New York 10016 United States Details
Research Site RECRUITING Nashville Tennessee 37203 United States Details
Research Site WITHDRAWN Dallas Texas 75235 United States Details
Research Site RECRUITING Houston Texas 77030 United States Details
Research Site RECRUITING Charlottesville Virginia 22903 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field